EyePoint (EYPT) Acquisitions (2018)

EyePoint (EYPT) posted Acquisitions of $16.8 million for Q3 2018, up 200.0% sequentially from -$16.8 million in Q2 2018.

Analysis

EyePoint (EYPT) Acquisitions (2018) Analysis & Trends

EyePoint has reported Acquisitions for 1 years, with the latest figure at $16.8 million in Q3 2018.

Quarterly Acquisitions changed N/A year-over-year to $16.8 million in Q3 2018, while the trailing twelve-month figure through Sep 2019 was $16.8 million (up 11.33% YoY) and the FY2018 annual result came in at $16.8 million, changed N/A from the prior year.
Acquisitions climbed to $16.8 million in Q3 2018 per EYPT's latest filing, from -$16.8 million in the prior quarter.
Over five years, Acquisitions peaked at $16.8 million in Q3 2018 and troughed at -$16.8 million in Q2 2018.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	-
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
10	EyePoint	398.53 Mn	218.06 Mn	507,000.00	-

Historic Data

Download Data